Edition:
United Kingdom

bluebird bio Inc (BLUE.OQ)

BLUE.OQ on NASDAQ Stock Exchange Global Select Market

103.43USD
18 Dec 2018
Change (% chg)

-- (--)
Prev Close
$103.43
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
217,917
52-wk High
$236.05
52-wk Low
$99.30

Latest Key Developments (Source: Significant Developments)

Regeneron & Bluebird Bio To Collaborate To Develop New Cell Therapies For Cancer
Monday, 6 Aug 2018 

Aug 6 (Reuters) - bluebird bio Inc ::REGENERON AND BLUEBIRD BIO ANNOUNCE COLLABORATION TO DISCOVER, DEVELOP AND COMMERCIALIZE NEW CELL THERAPIES FOR CANCER.REGENERON PHARMACEUTICALS INC - WILL ALSO MAKE A $100 MILLION INVESTMENT IN BLUEBIRD BIO COMMON STOCK AT A PRICE OF $238.10 PER SHARE.REGENERON PHARMACEUTICALS - CO, BLUEBIRD BIO SELECTED 6 INITIAL TARGETS, WILL EQUALLY SHARE COSTS OF RESEARCH AND DEVELOPMENT UP TO POINT OF SUBMITTING IND APPLICATION.  Full Article

Bluebird Bio And Regeneron Announce Collaboration To Discover, Develop And Commercialize New Cell Therapies For Cancer
Monday, 6 Aug 2018 

Aug 6 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO AND REGENERON ANNOUNCE COLLABORATION TO DISCOVER, DEVELOP AND COMMERCIALIZE NEW CELL THERAPIES FOR CANCER.BLUEBIRD BIO - CO, REGENERON WILL SPECIFICALLY LEVERAGE REGENERON'S VELOCISUITE PLATFORM TECHNOLOGIES FOR DISCOVERY OF FULLY HUMAN ANTIBODIES.BLUEBIRD BIO - CO, REGENERON HAVE SELECTED 6 TARGETS & WILL EQUALLY SHARE COSTS OF RND UP TO POINT OF SUBMITTING AN INVESTIGATIONAL NEW DRUG APPLICATION.  Full Article

Bluebird Bio Reports Q2 Loss Per Share $2.91
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS.Q2 REVENUE $7.9 MILLION VERSUS I/B/E/S VIEW $9.6 MILLION.ENDED QUARTER WITH $1.46 BILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES.QTRLY LOSS PER SHARE $2.91.Q2 EARNINGS PER SHARE VIEW $-2.35, REVENUE VIEW $9.6 MILLION -- THOMSON REUTERS I/B/E/S.ANTICIPATE FILING FIRST POTENTIAL REGULATORY APPROVAL IN EUROPE WITH LENTIGLOBIN TO TREAT TDT IN H2 2018.  Full Article

Bluebird Bio Announces Public Offering Of 3.4 Mln Shares Priced At $162.50 Per Share
Wednesday, 25 Jul 2018 

July 24 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 3.4 MILLION SHARES OF COMMON STOCK AT PUBLIC OFFERING PRICE OF $162.50 PER SHARE.  Full Article

• BLUEBIRD BIO SAYS CELGENE AMENDED PHASE 2 STUDY PROTOCOL
Thursday, 12 Jul 2018 

July 12 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO - CO, CELGENE CONTINUE TO ANTICIPATE A POTENTIAL APPROVAL OF BB2121 PRODUCT CANDIDATE IN RELAPSED & REFRACTORY MULTIPLE MYELOMA IN 2020.BLUEBIRD BIO SAYS CELGENE HAS AMENDED STUDY PROTOCOL FOR KARMMA STUDY, AN ONGOING PHASE 2 STUDY OF BB2121 PRODUCT CANDIDATE - SEC FILING.BLUEBIRD BIO - DOSE RANGE FOR KARMMA STUDY WILL BE 150 TO 450 X 10(6)CAR+ T CELLS AND ENROLLMENT WILL INCREASE TO UP TO 140 PATIENTS.BLUEBIRD BIO INC - IN ADDITION, CELGENE HAS AMENDED STUDY PROTOCOL FOR CRB-401, AN ONGOING PHASE I STUDY OF BB2121 PRODUCT CANDIDATE.BLUEBIRD BIO INC - ENROLLMENT FOR CRB-401 STUDY WILL BE INCREASED BY UP TO 20 PATIENTS, WITH A DOSE RANGE OF 150 TO 450 X 10(6)CAR+ T CELLS.  Full Article

FDA Grants Breakthrough Therapy Designation To Lenti-D For The Treatment Of Cerebral Adrenoleukodystrophy
Wednesday, 23 May 2018 

May 23 (Reuters) - bluebird bio Inc ::FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION TO LENTI-D™ FOR THE TREATMENT OF CEREBRAL ADRENOLEUKODYSTROPHY.BLUEBIRD BIO INC - BREAKTHROUGH THERAPY DESIGNATION IS SUPPORTED BY PRELIMINARY DATA FROM ONGOING PHASE 2/3 STARBEAM STUDY (ALD-102).  Full Article

Bluebird Bio Expects Three Regulatory Filings By End 2019
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Bluebird Bio Inc ::BLUEBIRD BIO CEO SAYS EXPECTS THREE REGULATORY FILINGS BY END 2019.BLUEBIRD SEES FILING FOR APPROVAL IN BETA THALASSEMIA IN 2018.BLUEBIRD BIO SEES FILING FOR US AND EU APPROVAL OF B2121 FOR MULTIPLE MYELOMA IN 2019.  Full Article

Bluebird Bio Prices Public Offering Of 3.2 Mln Shares At $185/Share
Wednesday, 13 Dec 2017 

Dec 12 (Reuters) - Bluebird Bio Inc ::BLUEBIRD BIO ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.‍PRICED UNDERWRITTEN PUBLIC OFFERING OF 3.2 MILLION SHARES OF ITS COMMON STOCK AT $185 PER SHARE​.  Full Article

Bluebird Bio Announces Proposed Public Offering Of Common Stock
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Bluebird Bio Inc ::BLUEBIRD BIO ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.BLUEBIRD BIO INC - HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $600 MILLION OF ITS COMMON STOCK.  Full Article

bluebird bio And TC BioPharm Announce Strategic Collaboration
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO AND TC BIOPHARM ANNOUNCE STRATEGIC COLLABORATION TO RESEARCH AND DEVELOP GAMMA DELTA CAR T CELL PRODUCT CANDIDATES FOR CANCER IMMUNOTHERAPY.BLUEBIRD BIO INC - FINANCIAL TERMS OF AGREEMENT INCLUDE A $16 MILLION UPFRONT PAYMENT.BLUEBIRD BIO - FINANCIAL TERMS OF AGREEMENT ALSO INCLUDE POTENTIAL RESEARCH AND DEVELOPMENT, COMMERCIAL MILESTONE PAYMENTS.BLUEBIRD BIO - AS PART OF DEAL, TC BIOPHARM ALSO ELIGIBLE TO GET UNDISCLOSED TIERED ROYALTIES ON PRODUCT SALES.BLUEBIRD BIO INC - CO, TC BIOPHARM WILL WORK TOGETHER TO ADVANCE TC BIOPHARM'S LEAD CAR-ENGINEERED GAMMA DELTA T CELL PROGRAM INTO CLINICAL TRIALS.  Full Article

Photo

Amgen antibody shows promise in myeloma trial, gets FDA fast track

SAN DIEGO Amgen Inc , updating the first trial of its bispecific antibody for multiple myeloma, said on Monday seven out of 10 patients given the second-highest dose of AMG420 responded to the drug, including four with no detectable cancer.